Status:
ACTIVE_NOT_RECRUITING
Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer
Lead Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborating Sponsors:
BeiGene
Conditions:
Esophagus Cancer
Neoadjuvant Therapy
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Neoadjuvant chemoradiotherapy is recommended as standard therapy for resectable esophageal cancer. The recurrence rate after surgery following neoadjuvant chemoradiotherapy is about 35%. Whether achie...
Eligibility Criteria
Inclusion
- Main Inclusion Criteria:
- Pathologically diagnosed as esophageal squamous cell carcinoma
- Initially diagnosed as thoracic esophageal cancer
- resectable or potantially resectable
- II-IVA according to AJCC 8th edition；
- KPS≥70
- Adequate organ function
Exclusion
Key Trial Info
Start Date :
January 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 15 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04776590
Start Date
January 28 2021
End Date
December 15 2024
Last Update
April 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Union Hospital
Wuhan, Hubei, China, 430022